You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed or Refractory Hodgkin's Lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hodgkin Lymphoma Trial in Moscow (Nivolumab)

Recruiting
  • Hodgkin Lymphoma
  • Moscow, Russian Federation
    National Research Center for Hematology
Dec 13, 2022

Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult Trial in Leon (Brentuximab Vedotin 50 MG

Recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Brentuximab Vedotin 50 MG [Adcetris]
  • Leon, Guanajuato, Mexico
    Hospital Regional Alta Especialidad Bajio
Oct 24, 2022

Hodgkin's Lymphoma Trial in Houston (Azacytidine, Pembrolizumab)

Recruiting
  • Hodgkin's Lymphoma
  • Houston, Texas
    MD Anderson Cancer Center
Oct 5, 2022

Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

Recruiting
  • Relapsed Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Nivolumab
  • Pembrolizumab
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Jul 22, 2022

Non-hodgkin Lymphoma Trial (HY004)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • HY004
  • (no location specified)
Aug 21, 2023

Lymphoma, Non-Hodgkin's, Adult Trial (SP-3164)

Not yet recruiting
  • Lymphoma, Non-Hodgkin's, Adult
  • (no location specified)
Aug 4, 2023

Hodgkin's Lymphoma Trial in Milan (histone deacetylase inhibitor (ITF2357))

Terminated
  • Hodgkin's Lymphoma
  • histone deacetylase inhibitor (ITF2357)
  • Milan, Italy
    Istituto Nazionale per lo studio e la cura dei Tumori
Jan 18, 2022

Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)

Recruiting
  • Relapsed or Refractory Hodgkin Lymphoma
  • Beijing, Beijing, China
    Han wei dong
Jun 14, 2023

Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Advanced Solid Tumor Trial (TR115)

Not yet recruiting
  • Non-Hodgkin's Lymphoma, Relapsed
  • +2 more
  • (no location specified)
Dec 6, 2022

Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Duarte, Hackensack, Houston (SIRPant-M, External-beam

Not yet recruiting
  • Refractory Non-Hodgkin Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • SIRPant-M
  • External-beam radiotherapy (XRT)
  • Duarte, California
  • +2 more
Jul 21, 2023

Hodgkin Lymphoma Trial (Gemcitabine, Dexamethasone, Cisplatin)

Not yet recruiting
  • Hodgkin Lymphoma
  • (no location specified)
May 9, 2022

CD20-positive B-cell Non-Hodgkin's Lymphoma Trial in Beijing (IMM0306)

Recruiting
  • CD20-positive B-cell Non-Hodgkin's Lymphoma
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Apr 6, 2023

SALVAGE TREATMENT WITH GLOFITAMAB IN RELAPSED/REFRACTORY B-NHL:

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • +2 more
    • (no location specified)
    Jun 22, 2023

    Hodgkin Lymphoma Trial in Moscow (Nivolumab)

    Recruiting
    • Hodgkin Lymphoma
    • Moscow, Russian Federation
      The Federal Budget-Funded Institution National Medical Surgical
    Oct 31, 2022

    Relapsed/Refractory Non-Hodgkin Lymphoma Trial in Duarte, Amsterdam (BMS-986458, Rituximab)

    Not yet recruiting
    • Relapsed/Refractory Non-Hodgkin Lymphoma
    • Duarte, California
    • +1 more
    Oct 13, 2023

    Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)

    Recruiting
    • Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
    • dualCAR-NK19/70 cell
    • Shanghai, Shanghai, China
      Shanghai Tongji Hospital, Tongji University School of Medicine
    Apr 24, 2023

    Non-hodgkin's Lymphoma Trial in Beijing (GNC-035)

    Not yet recruiting
    • Non-hodgkin's Lymphoma
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Sep 27, 2023

    Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Trial in Isehara, Chuo-ku (tazemetostat)

    Completed
    Has Results
    • Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
    • Isehara, Kanagawa, Japan
    • +1 more
    Apr 6, 2022

    Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Trial (C-CAR066)

    Not yet recruiting
    • Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
    • (no location specified)
    Mar 23, 2023

    Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Trial in Beijing (JS203 for Injection)

    Not yet recruiting
    • Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
    • JS203 for Injection
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Nov 11, 2022

    Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed Trial in United States (MT-601)

    Recruiting
    • Non-Hodgkin Lymphoma, Adult
    • +3 more
    • Duarte, California
    • +3 more
    Apr 4, 2023

    Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

    Not yet recruiting
    • Non-hodgkin Lymphoma
    • +9 more
    • CD79b-19 CAR T cells
    • +2 more
    • Boston, Massachusetts
      Massachusetts General Hospital
    Sep 6, 2023

    Non-hodgkin Lymphoma Trial (CD38-SADA:177Lu-DOTA Complex)

    Not yet recruiting
    • Non-hodgkin Lymphoma
    • CD38-SADA:177Lu-DOTA Complex
    • (no location specified)
    Aug 15, 2023

    Relapsed or Refractory Non-Hodgkin's Lymphoma Trial in China (AXT-1003)

    Not yet recruiting
    • Relapsed or Refractory Non-Hodgkin's Lymphoma
    • Beijing, China
    • +3 more
    Jul 20, 2023

    Relapsed or Refractory Non-Hodgkin's Lymphoma Trial in Changsha, Suzhou (U16)

    Recruiting
    • Relapsed or Refractory Non-Hodgkin's Lymphoma
    • Changsha, Hunan, China
    • +1 more
    Mar 13, 2023